The rodent studies in which the peptide was tested against the gastric and intestinal damage of anti-inflammatory drugs

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Non-steroidal anti-inflammatory drugs given to rodents in high amounts produce reproducible gastric ulceration, small-intestinal damage, and at the amounts used in some models liver and nervous-system toxicity. The Zagreb group has published a series of studies in which BPC-157 was given alongside aspirin, diclofenac, ibuprofen, indomethacin or paracetamol, reporting smaller gastric lesions, less intestinal injury, and in the high-amount models reduced liver enzyme rises and reduced behavioural toxicity. The group frames this as the peptide counteracting NSAID toxicity through its vascular and nitric oxide mechanisms. The models are standard pharmacology; the breadth of protection claimed across organs is the feature a reader should weigh.

The models

NSAID-induced gastric injury is one of the oldest cytoprotection models, with lesion area measured after a single large amount of the drug; it was among the first BPC-157 was tested in. Intestinal injury from indomethacin, with ulceration of the small bowel, is a later and more severe model. The high-amount diclofenac and ibuprofen models produce liver injury and, the group reports, behavioural changes, and the peptide was tested against those too.

Each is a controlled comparison in rats with objective endpoints, in the pattern of the wider literature.

The claims and their shape

Protection is reported in every organ and against every drug tested, which is either a broadly protective molecule or the pattern a single-source literature produces; the two cannot be told apart from inside it. The mechanism offered is the same vascular and nitric oxide account used across the literature. No independent group has published a replication of the NSAID models, and no human data exist.

The models are also those in which the compound was originally characterised as cytoprotective, so the strand is continuous with the 1993 origin.

Why it is here

Because the NSAID studies are among the most cited and most quoted, and a reader should know what they are. It describes studies and no use of the pack.

The BPC-157 + TB500 blend is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for each component of the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
BPC-157 + TB500 Pack5 mg + 5 mgAED 510In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The models?

NSAID-induced gastric injury is one of the oldest cytoprotection models, with lesion area measured after a single large amount of the drug; it was among the first BPC-157 was tested in. Intestinal injury from indomethacin, with ulceration of the small bowel, is a later and more severe model. The high-amount diclofenac and ibuprofen models produce liver injury and, the group reports, behavioural changes, and the peptide was tested against those too.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

BPC-157 + TB500 Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.